iBio (NASDAQ:IBIO) versus Gemini Therapeutics (NASDAQ:GMTX) Critical Review

iBio (NASDAQ:IBIO) and Gemini Therapeutics (NASDAQ:GMTX) are both manufacturing companies, but which is the superior stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, risk, valuation and earnings.

Valuation and Earnings

This table compares iBio and Gemini Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iBio	$300,000.00	324.71	-$18.38 million	($1.00)	-2.82
Gemini Therapeutics	N/A	N/A	-$71.87 million	($1.00)	-66.62

iBio has higher revenue and earnings than Gemini Therapeutics. Gemini Therapeutics is trading at a lower price-to-earnings ratio than iBio, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares iBio and Gemini Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
iBio	N/A	-71.26%	-57.92%
Gemini Therapeutics	N/A	-38.78%	-35.88%

Risk & Volatility

iBio has a beta of 1.26, indicating that its stock price is 26% more volatile than the S&P 500. Comparatively, Gemini Therapeutics has a beta of -0.12, indicating that its stock price is 112% less volatile than the S&P 500.

Institutional and Insider Ownership

7.9% of iBio shares are owned by institutional investors. Comparatively, 75.4% of Gemini Therapeutics shares are owned by institutional investors. 2.8% of iBio shares are owned by company insiders. Comparatively, 12.9% of Gemini Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings and target prices for iBio and Gemini Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iBio	1	0	0	2	3.00
Gemini Therapeutics	0	0	0	0	0.00

Summary

iBio beats Gemini Therapeutics on 6 of the 10 factors compared between the two stocks.

About iBio

iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.

About Gemini Therapeutics

Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.